文献速递消化系统肿瘤

结直肠癌中PTGS2(COX-2)过表达与BRAF突变状态相关的预后关联:来自两个前瞻性队列和CALGB 89803(Alliance)试验的结果

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
PubMed 文献 · Eur J Cancer · 2019-03-01

研究纳入1708例结直肠癌患者(NHS和HPFS队列1200例I-IV期,CALGB/Alliance 89803试验508例III期结肠癌),用免疫组化评估肿瘤PTGS2(COX-2)表达,按BRAF突变状态分层分析预后关联。NHS和HPFS中,PTGS2高表达与结直肠癌特异性生存的关联随BRAF状态不同(交互作用P=0.0005),BRAF突变者风险比2.44(95%CI 1.39-4.28),BRAF野生型者0.82(95%CI 0.65-1.04);CALGB/Alliance 89803试验也观察到类似差异(交互作用P=0.03)。结论认为PTGS2表达与结直肠癌死亡率的关联在BRAF突变肿瘤中更强。

要点

  • 在NHS和HPFS队列中,PTGS2高表达与结直肠癌特异性生存的关联因BRAF突变状态而异(交互作用P=0.0005)。
  • BRAF突变病例中,PTGS2高表达vs阴性/低表达的多变量校正HR为2.44(95%CI 1.39-4.28)。
  • BRAF野生型病例中,PTGS2高表达vs阴性/低表达的多变量校正HR为0.82(95%CI 0.65-1.04)。

核心结论

  • 肿瘤PTGS2(COX-2)表达与结直肠癌死亡率的关联在BRAF突变肿瘤中比在BRAF野生型肿瘤中更强,支持PTGS2表达和BRAF突变状态在结直肠癌预后判断中的交互作用。

研究设计与样本

  • 研究纳入1708例患者,包括Nurses' Health Study(NHS)和Health Professionals Follow-up Study(HPFS)中1200例I-IV期结直肠癌病例,以及美国国家癌症研究所资助的辅助治疗随机对照试验CALGB/Alliance 89803中508例III期结肠癌病例。
  • 采用免疫组化评估肿瘤PTGS2(COX-2)表达状态,并用多变量Cox比例风险回归模型按BRAF突变状态分层分析预后关联,校正疾病分期、肿瘤分化、微卫星不稳定状态及KRAS和PIK3CA突变等潜在混杂因素。

主要发现

  • 在NHS和HPFS中,PTGS2(COX-2)表达与结直肠癌特异性生存的关联因BRAF突变状态而异(交互作用P=0.0005)。
  • 与PTGS2(COX-2)阴性/低表达癌相比,PTGS2(COX-2)高表达癌的多变量校正风险比在BRAF突变病例中为2.44(95%CI 1.39-4.28),在BRAF野生型病例中为0.82(95%CI 0.65-1.04)。
  • 在CALGB/Alliance 89803试验中同样观察到PTGS2(COX-2)表达按BRAF突变状态分层的预后关联差异(交互作用P=0.03)。

关键数值与推荐

  • NHS和HPFS中,PTGS2高表达vs阴性/低表达的结直肠癌特异性生存多变量校正HR:BRAF突变病例2.44(95%CI 1.39-4.28),BRAF野生型病例0.82(95%CI 0.65-1.04),交互作用P=0.0005。
  • CALGB/Alliance 89803试验中,PTGS2表达与BRAF突变状态的交互作用P=0.03。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase-2, COX-2)-prostaglandin E2 (PGE2) pathway promotes tumour progression. Considering evidence suggesting increased PGE2 synthesis by BRAF mutation in tumour cells, we hypothesised that the association of tumour PTGS2 (COX-2) expression with colorectal cancer mortality might be stronger in BRAF-mutated tumours than in BRAF-wild-type tumours. METHODS: Using 1708 patients, including 1200 stage I-IV colorectal carcinoma cases in the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) and 508 stage III colon cancer cases in a National Cancer Institute-sponsored randomised controlled trial of adjuvant therapy (CALGB/Alliance 89803), we evaluated tumour PTGS2 (COX-2) expression status using immunohistochemistry. We examined the prognostic association of PTGS2 (COX-2) expression in strata of BRAF mutation status by multivariable Cox proportional hazards regression models to adjust for potential confounders, including disease stage, tumour differentiation, microsatellite instability status and KRAS and PIK3CA mutations. RESULTS: In NHS and HPFS, the association of PTGS2 (COX-2) expression with colorectal cancer-specific survival differed by BRAF mutation status (Pinteraction = 0.0005); compared with PTGS2 (COX-2)-negative/low carcinomas, the multivariable-adjusted hazard ratios for PTGS2 (COX-2)-high carcinomas were 2.44 (95% confidence interval, 1.39-4.28) in BRAF-mutated cases and 0.82 (95% confidence interval, 0.65-1.04) in BRAF-wild-type cases. Differential prognostic associations of PTGS2 (COX-2) expression in strata of BRAF mutation status were similarly observed in CALGB/Alliance 89803 trial (Pinteraction = 0.03). CONCLUSIONS: The association of tumour PTGS2 (COX-2) expression with colorectal cancer mortality is stronger in BRAF-mutated tumours than in BRAF-wild-type tumours, supporting interactive roles of PTGS2 (COX-2) expression and BRAF mutation statuses in prognostication of patients with colorectal cancer; ClinicalTrials.gov Identifier, NCT00003835.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kosumi K, Hamada T, Zhang S, et al. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. Eur J Cancer. 2019. PMID: 30826660. doi:10.1016/j.ejca.2019.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。